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Amid the dire statistics showing a deadly resurgence of malaria, a notable success 
has been scored in South Africa. In 
KwaZulu–Natal province, malaria 
cases increased from about 600 in 
1991–1992 to more than 30,000 by 
1999–2000 [1]. Then, after household 
spraying with DDT was implemented, 
and the new antimalarial combination 
artemether-lumefantrine (AL) was 
widely deployed (Figure 1), cases 
declined by more than 99% over the 
next three years. A paper in PLoS 
Medicine by Barnes et al. [2] examines 
the implementation and efﬁ cacy of 
AL during the KwaZulu–Natal crisis. 
They conclude that vector control and 
widespread use of artemisinin-based 
combination therapy (ACT) such 
as AL may confer similar beneﬁ ts in 
other African countries. Could the 
adoption of these policies salvage the 
Roll Back Malaria Initiative that was 
formed in 1999 to halve malaria deaths 
by 2010 [3], but which was recently 
lamented as “dysfunctional” for its 
inaction in the face of rising malaria 
morbidity and mortality rates [4]?
Artemisinins to the Rescue
Artemisinin derivatives such as 
artemether have several advantages—
they act rapidly, cause few side 
effects, and have not yet acquired 
resistant parasites [5]. Artemisinins 
also prevent parasite transmission by 
inactivating or killing gametocytes 
[6]. In northwestern Thailand, 
malaria incidence declined after 
the ACT artesunate-meﬂ oquine was 
introduced, and its effectiveness has 
been sustained over several years, 
possibly due to gametocytocidal effects 
[7]. In a study recently published 
in PLoS Medicine [6], gametocytes 
from Gambian children treated with 
AL were less likely than those from 
children treated with a chloroquine 
and sulfadoxine-pyrimethamine (SP) 
combination to infect mosquitoes. 
These reports have led many to expect 
that ACTs will dramatically improve 
case management, and reduce malaria 
transmission in Africa.
KwaZulu–Natal—A Special Case?
Caution is warranted, however. 
KwaZulu–Natal is more similar to 
Thailand than to most sub-Saharan 
countries in ways that may affect the 
inﬂ uence of ACTs. The economic 
strength of South Africa supported 
effective vector control measures 
and a health-care infrastructure 
that facilitated prompt diagnosis 
and treatment. Poorer sub-Saharan 
countries are unable to support similar 
programs in the absence of additional 
ﬁ nancial resources.
Noneconomic issues may also limit 
the effect of ACTs on malaria incidence 
and case management in Africa. 
Malaria transmission and, therefore, 
immunity are low in both Thailand 
and KwaZulu–Natal. Thais and South 
Africans typically get sick when they 
are infected, and seek treatment. 
In African countries where malaria 
transmission is high, semi-immune 
individuals often do not feel sick 
enough to seek treatment, and act as a 
reservoir for continued transmission. 
Additionally, African children often 
present with high-density parasitemia, 
making it more likely that parasites will 
be temporarily suppressed but then 
recrudesce after artemisinin therapy 
[8,9].  
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Figure 1. Mosquito Control and ACT Are Both Likely Contributors to the Reduction of Malaria 
in KwaZulu–Natal 
(Photo: Karen Barnes and Atis Muelenbachs)
PLoS Medicine  |  www.plosmedicine.org 1077
ACTs will improve treatment 
outcomes in areas of sub-Saharan 
Africa where resistant parasites have 
rendered the current ﬁ rst-line drugs 
nearly useless. Drug resistance has 
probably played a key role in the rising 
malaria mortality rates among African 
children [10], so ministries of health 
are optimistic that ACTs will reverse 
this awful trend. However, the long-
term effectiveness of ACTs in high 
endemicity areas has not been proven, 
and many operational questions remain 
unanswered.
ACT Alternatives
Are ACTs the most effective new 
antimalarial combination? In the 
July issue of PLoS Medicine, Dorsey 
and colleagues reported that the 
nonartemisinin combination of SP and 
amodiaquine (AQ) was as effective 
or better (and cheaper) than the 
combination of artesunate and AQ for 
treating Ugandan children, when both 
recrudescent and new infections were 
considered [11]. Resistance to both 
SP and AQ is spreading in Africa, and 
this will limit the sustainability of the 
combination. Furthermore, because 
recrudescent parasites are more 
likely to be drug-resistant [12], and 
recrudescences were more common 
after SP-AQ, this combination may 
accelerate the spread of resistant 
parasites. Nevertheless, the 
combination should be considered as 
a short-term strategy in areas where 
the parasite remains sensitive. The 
results also caution that the beneﬁ ts 
of ACTs may be limited in high 
endemicity areas unless reinfections 
are promptly treated.
Is AL the Best ACT for Africa? 
AL is the only co-formulated 
ACT, which improves compliance. 
Furthermore, a dramatic rollback of 
malaria has been achieved in KwaZulu–
Natal where AL was deployed. These 
have been strong factors in the 
selection of AL as ﬁ rst-line therapy 
by many African countries. However, 
the sharp decline in malaria in 
KwaZulu–Natal commenced after DDT 
spraying of households was initiated 
and before AL was deployed; therefore, 
the relative contribution of AL remains 
unclear. Sustained success with ACTs 
in Thailand has been achieved with 
artemether-meﬂ oquine. The long-term 
effectiveness of AL remains unproven. 
The extended half-life of lumefantrine 
and the short half-life of artesunate 
mean that many reinfections in Africa 
will be exposed to lumefantrine alone, 
increasing the odds that resistant 
parasites will be selected. Worrying 
reports from Zanzibar suggest that 
lumefantrine resistance may already 
be emerging there, not long after 
AL was introduced as second-line 
therapy [13]. Future studies should 
compare different artemisinin and 
nonartemisinin combination therapies 
for their long-term effectiveness. 
Finally, the huge new market for AL 
in Africa has outstripped the available 
supplies, delaying the launch of ACTs 
in some countries, and it remains 
uncertain when these supply problems 
will be fully resolved.
Learning from Success
Will ACTs “roll back malaria”? The 
Barnes et al. paper focuses on the 
efﬁ cacy and implementation of 
AL in KwaZulu–Natal, but active 
surveillance and treatment for 
asymptomatic carriers [1], as well as 
residual spraying, contributed to the 
success. Barnes et al. argue for an 
effective vector control program and 
ACT implementation in the context 
of a well-developed rural primary 
health-care infrastructure. While the 
cost of executing these programs 
throughout Africa may seem great, 
the cost of not doing so is likely to be 
greater, especially if resistance to ACTs 
emerges as a consequence. In any case, 
the widespread expectation that ACTs 
alone will turn the tide in the ﬁ ght 
against malaria may be unrealistic. 
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